Opus Genetics completes cohort 1 enrollment in Phase 1/2 OPGx-BEST1 gene therapy study

Opus Genetics, Inc.

IRD

0.00

Opus Genetics completed enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 gene therapy study in adults with Best disease, setting up a near-term readout for program momentum.
Cohort 1 enrolled 5 participants across dominant and recessive forms; 4 have been treated, with final dosing scheduled this month.
Baseline demographics were presented at ARVO, with 3-month results from first treated participant indicating the therapy was well tolerated with early signs of biological activity.
Three-month topline results for full Cohort 1 will be released in September 2026, with a broader data presentation planned at an ophthalmology conference later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.